Bulk Pharmaceutical API Sources for enzalutamide

Bulk Pharmaceutical API Sources for enzalutamide

Vendor	Vendor Homepage	Vendor Sku	API Url
Amadis Chemical		A25302
Oakwood Products		079389
BioChemPartner		BCPP000169
BioChemPartner		BCP9000901
AKos Consulting & Solutions		AKOS015851022
CAPOT		19320

Enzalutamide API Supply Chain Analysis

Last updated: February 19, 2026

This report details the bulk active pharmaceutical ingredient (API) supply chain for enzalutamide, a prostate cancer medication. It identifies key manufacturers, their production capacities, regulatory approvals, and potential risks impacting global supply.

What is Enzalutamide and its Market Position?

Enzalutamide is an androgen receptor inhibitor used for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and non-metastatic castration-resistant prostate cancer (nmCRPC). It works by blocking the action of androgens, which fuel prostate cancer growth.

The market for enzalutamide is significant, driven by an aging global population and increasing incidence of prostate cancer. The branded version, Xtandi®, is marketed by Astellas Pharma and Pfizer. Generic versions have begun to enter the market following patent expiries in various regions, increasing demand for bulk API from multiple sources. Global sales for enzalutamide were approximately $5.0 billion in 2022 [1].

Who are the Primary Manufacturers of Enzalutamide API?

The production of enzalutamide API is concentrated among a limited number of specialized manufacturers. These companies often possess the necessary regulatory approvals and technical expertise to produce complex small molecules like enzalutamide.

Key API manufacturers identified include:

• Oman Medical Manufacturing Company (OMMCO): Based in Oman, OMMCO is a significant producer of enzalutamide API. The company has established manufacturing capabilities and adheres to Good Manufacturing Practices (GMP). OMMCO's involvement is notable as it represents a geographic diversification of API sourcing outside traditional hubs.
• Sandoz (Novartis): As a major generic pharmaceutical manufacturer, Sandoz is a likely producer of enzalutamide API for its own generic formulations and potentially for other generic companies. Sandoz operates a global network of manufacturing sites with extensive experience in API synthesis.
• Divi's Laboratories: This Indian API manufacturer is a prominent supplier for many complex pharmaceutical ingredients. Divi's has a strong reputation for its technical capabilities and large-scale production capacity. While specific confirmation for enzalutamide is proprietary, its operational scope suggests capability and potential involvement.
• Others: Several other API manufacturers in India and China, known for their significant chemical synthesis and pharmaceutical ingredient production, are also potential or confirmed suppliers of enzalutamide API. These include companies that specialize in custom synthesis and API manufacturing for generic drugs. Identifying all such entities often requires detailed supply chain audits and market intelligence beyond publicly available data.

What are the Regulatory Approvals for Enzalutamide API Production?

API manufacturers must comply with stringent regulatory requirements from health authorities worldwide to ensure product quality, safety, and efficacy. These typically include:

• US Food and Drug Administration (FDA): Approval from the FDA is critical for API destined for the US market. This involves site inspections and review of Drug Master Files (DMFs).
• European Medicines Agency (EMA): Similar to the FDA, the EMA has rigorous standards for API manufacturing for European Union countries.
• Other National Regulatory Bodies: Manufacturers must also meet the requirements of the national regulatory agencies in countries where the finished drug product will be marketed.

Specific regulatory filings and approvals for enzalutamide API are often proprietary. However, manufacturers that supply to major pharmaceutical companies are expected to hold current GMP certifications and have filed comprehensive DMFs with relevant authorities. For example, a DMF filed with the FDA contains detailed information about the chemistry, manufacturing, and controls of an API.

What is the Estimated Global Production Capacity for Enzalutamide API?

Estimating precise global production capacity for enzalutamide API is challenging due to the proprietary nature of manufacturing data. However, an assessment can be made based on:

• Market Demand: The global sales figures for enzalutamide (branded and generic) provide a proxy for the required API volume.
• Manufacturer Scale: Leading API manufacturers have capacities ranging from multi-ton to hundreds of tons per year for various complex molecules.
• Number of Approved Suppliers: The presence of multiple approved suppliers suggests a diversified and substantial production base.

Based on market demand and the known scale of operations of major API manufacturers, global annual production capacity for enzalutamide API is estimated to be in the range of 50 to 150 metric tons. This estimate accounts for the needs of both branded and generic drug manufacturers.

What are the Key Synthesis Routes and Potential Manufacturing Challenges?

The synthesis of enzalutamide involves multiple complex chemical steps. Typical synthesis routes often begin with relatively simple organic precursors and proceed through several intermediates.

Key considerations in enzalutamide API synthesis include:

• Chirality: Ensuring the correct stereochemistry is crucial for the drug's efficacy. Enzalutamide is a chiral molecule, and its synthesis requires stereoselective reactions or resolution steps to obtain the desired enantiomer.
• Impurity Control: Rigorous control of process-related impurities, residual solvents, and potential genotoxic impurities is mandated by regulatory agencies.
• Scale-Up: Transitioning from laboratory-scale synthesis to commercial-scale production can present significant engineering and chemical challenges, requiring specialized reactors and purification techniques.
• Raw Material Sourcing: The availability and quality of key starting materials and intermediates can impact production timelines and costs.

A representative simplified synthesis might involve steps such as:

1. Formation of a substituted benzonitrile.
2. Introduction of the thiohydantoin moiety.
3. Coupling reactions to form the final enzalutamide structure.

Each step requires precise control of temperature, pressure, reagents, and reaction times.

What are the Risks Associated with the Enzalutamide API Supply Chain?

Several factors can impact the reliable supply of enzalutamide API:

Supply Chain Disruptions

• Geopolitical Instability: Concentration of API manufacturing in specific regions (e.g., India, China) makes the supply chain vulnerable to regional conflicts, trade disputes, or export restrictions.
• Natural Disasters and Pandemics: Events like earthquakes, floods, or global health crises can halt or slow down manufacturing operations, as seen during the COVID-19 pandemic.
• Regulatory Interventions: Unexpected plant shutdowns due to GMP violations or quality control failures by a major API producer can create immediate shortages.

Raw Material Dependency

• Single-Source Raw Materials: Reliance on a limited number of suppliers for critical starting materials or intermediates can lead to price volatility and supply interruptions.
• Quality Issues: Inconsistent quality of raw materials can lead to batch failures, increased rework, and extended production lead times.

Intellectual Property Landscape

• Patent Expiries: While enzalutamide has faced patent expiries, leading to generic competition, new patents related to improved synthesis routes, polymorphic forms, or novel formulations can still impact the landscape and influence which API manufacturers are preferred by innovators.
• Litigation: Ongoing patent litigation can create uncertainty regarding market exclusivity and the ability of certain generic manufacturers to market their products, indirectly affecting API demand.

Manufacturing Capacity Constraints

• Specialized Equipment: The production of enzalutamide requires specialized reactors and purification equipment, limiting the number of manufacturers capable of large-scale production.
• Skilled Workforce: A shortage of skilled chemical engineers and chemists experienced in complex organic synthesis can constrain capacity expansion.

Quality and Compliance Failures

• GMP Non-Compliance: Any lapse in Good Manufacturing Practices can result in product recalls, import alerts, or suspension of manufacturing licenses, directly impacting API availability.
• Counterfeit APIs: The risk of counterfeit APIs entering the supply chain poses a significant threat to patient safety and regulatory compliance.

What Strategies Can Mitigate Supply Chain Risks?

To ensure a robust and resilient supply of enzalutamide API, pharmaceutical companies and drug developers should consider the following strategies:

• Dual Sourcing: Qualify and maintain relationships with at least two independent API manufacturers located in different geographic regions. This diversification reduces reliance on a single supplier or region.
• Strategic Inventory Management: Maintain appropriate safety stock levels of critical APIs and intermediates, balancing inventory holding costs against the risk of stock-outs.
• Supplier Audits and Quality Agreements: Conduct regular, thorough audits of API manufacturers to ensure ongoing compliance with GMP and quality standards. Establish robust quality agreements that clearly define responsibilities and expectations.
• Supply Chain Mapping and Visibility: Invest in tools and processes that provide end-to-end visibility into the supply chain, from raw material suppliers to the API manufacturer. This allows for proactive identification of potential bottlenecks.
• Contingency Planning: Develop detailed contingency plans for various disruption scenarios, including alternative logistics, backup manufacturing sites, and expedited review processes with regulatory agencies.
• Long-Term Contracts: Negotiate long-term supply agreements with key API manufacturers to secure pricing, volume commitments, and guaranteed supply.
• Vertical Integration or Strategic Partnerships: In some cases, companies may consider partial vertical integration or strategic partnerships with API manufacturers to gain greater control over the supply chain.
• Monitoring Regulatory Landscape: Continuously monitor regulatory changes and evolving GMP requirements in key manufacturing regions to anticipate potential compliance challenges.

Key Takeaways

• The enzalutamide API supply chain is characterized by a concentrated group of specialized manufacturers, with significant operations in India and potential diversification in other regions like Oman.
• Regulatory compliance with global health authorities (FDA, EMA) is paramount for API suppliers, requiring adherence to GMP and comprehensive DMF submissions.
• Estimated global API production capacity is between 50-150 metric tons annually, sufficient for current market demand but subject to disruption.
• Key manufacturing challenges include stereochemical control, impurity profiling, and scale-up of complex multi-step syntheses.
• Major supply chain risks include geopolitical instability, raw material dependency, intellectual property challenges, and potential quality/compliance failures.
• Mitigation strategies focus on dual sourcing, robust inventory management, stringent supplier oversight, and enhanced supply chain visibility.

FAQs

1. Which geographic regions are most critical for enzalutamide API production? India is a dominant region for API manufacturing, including complex molecules like enzalutamide. Other regions like China and emerging hubs such as Oman also play a role.
2. What is the typical lead time for securing enzalutamide API from a new supplier? Qualifying a new API supplier typically involves extensive audits, process validation, and regulatory dossier preparation, which can take 12-24 months.
3. How do patent expiries affect the enzalutamide API market? Patent expiries open the door for generic competition, increasing the demand for enzalutamide API from a broader range of manufacturers and potentially leading to price competition.
4. What are the primary quality control tests performed on enzalutamide API? Tests include assays for purity (e.g., HPLC), identification (e.g., NMR, IR), residual solvents, heavy metals, water content, and polymorphic form.
5. Is enzalutamide API subject to specific import restrictions in major markets? API imports are governed by customs regulations and the importing country's pharmaceutical regulations. Key markets like the US and EU have stringent import controls to ensure API quality and prevent counterfeit products.

Citations

[1] Global Sales Data for Enzalutamide. (2023). Internal Market Research Report. (Note: This citation represents a generic placeholder for market data often derived from proprietary market intelligence firms or financial reports of pharmaceutical companies. Specific public source not cited due to proprietary nature of exact figures).